Editorial
Nature Biotechnology 25, 1375 (2007)
doi:10.1038/nbt1207-1375
Beyond interferon
Abstract
Interferon (IFN)-
has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.
